K
Kathleen J. Propert
Researcher at University of Pennsylvania
Publications - 164
Citations - 14375
Kathleen J. Propert is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Interstitial cystitis & Pelvic pain. The author has an hindex of 57, co-authored 163 publications receiving 13559 citations. Previous affiliations of Kathleen J. Propert include National Institutes of Health & Boston Medical Center.
Papers
More filters
Journal ArticleDOI
A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.
Robert O. Dillman,Stephen L. Seagren,Kathleen J. Propert,Julio Guerra,Walter L. Eaton,Michael C. Perry,Robert W. Carey,Emil Frei,Mark R. Green +8 more
TL;DR: In patients with Stage III non-small-cell lung cancer, induction chemotherapy with cisplatin and vinblastine before radiation significantly improves median survival and doubles the number of long-term survivors, as compared with radiation therapy alone.
Journal ArticleDOI
Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD
George P. Canellos,James R. Anderson,Kathleen J. Propert,Nis I. Nissen,M R Cooper,E S Henderson,Mark R. Green,Arlan J. Gottlieb,Bruce A. Peterson +8 more
TL;DR: ABVD therapy for 6 to 8 months was as effective as 12 months of MopP alternating with ABVD, and both were superior to MOPP alone in the treatment of advanced Hodgkin's disease.
Journal ArticleDOI
Immune responses to adenovirus and adeno-associated virus in humans.
Narendra Chirmule,Kathleen J. Propert,Susan Magosin,Y Qian,Ruth Qian,James M. Wilson,James M. Wilson +6 more
TL;DR: Significant heterogeneity in pre-existing immunity to Ad5 and AAV2 in human populations is demonstrated and the impact of these findings on outcome following gene therapy will require further study.
Journal ArticleDOI
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.
Marina Cuchel,Emma A. Meagher,Hendrik Du Toit Theron,Dirk J. Blom,Dirk J. Blom,A. David Marais,A. David Marais,Robert A. Hegele,Maurizio Averna,Cesare R. Sirtori,Prediman K. Shah,Daniel Gaudet,Claudia Stefanutti,Giovanni Battista Vigna,Anna M. E. Du Plessis,Kathleen J. Propert,William J. Sasiela,LeAnne T. Bloedon,Daniel J. Rader +18 more
TL;DR: Treatment with lomitapide could be a valuable drug in the management of homozygous familial hypercholesterolaemia, according to the FDA Office of the Orphan Product Development.
Journal ArticleDOI
Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Scott Saxman,Kathleen J. Propert,Lawrence H. Einhorn,E D Crawford,I Tannock,D Raghavan,Patrick J. Loehrer,D Trump +7 more
TL;DR: Long-term follow-up evaluation of the intergroup trial confirms that M-VAC is superior to single-agent cisplatin in patients with advanced urothelial carcinoma; however, durable progression-free survival is rare.